Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BBIO NASDAQ:RGC NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$234.63+4.2%$231.30$150.89▼$250.74$14.60B0.41693,896 shs324,608 shsBBIOBridgeBio Pharma$68.73-0.1%$71.29$31.77▼$84.94$13.44B1.022.72 million shs1.17 million shsRGCRegencell Bioscience$27.85+2.1%$27.06$3.93▼$83.60$13.77B1.88334,144 shs47,442 shsTVTXTravere Therapeutics$44.23-1.3%$32.31$13.88▼$48.61$4.08B1.132.15 million shs1.28 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+1.97%+1.56%-1.73%+2.53%+31.94%BBIOBridgeBio Pharma+0.32%-1.39%-5.97%-8.53%+79.96%RGCRegencell Bioscience-6.35%-6.13%-11.46%-3.91%+2,726,999,900.00%TVTXTravere Therapeutics+1.54%+9.56%+47.17%+41.41%+109.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$234.63+4.2%$231.30$150.89▼$250.74$14.60B0.41693,896 shs324,608 shsBBIOBridgeBio Pharma$68.73-0.1%$71.29$31.77▼$84.94$13.44B1.022.72 million shs1.17 million shsRGCRegencell Bioscience$27.85+2.1%$27.06$3.93▼$83.60$13.77B1.88334,144 shs47,442 shsTVTXTravere Therapeutics$44.23-1.3%$32.31$13.88▼$48.61$4.08B1.132.15 million shs1.28 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+1.97%+1.56%-1.73%+2.53%+31.94%BBIOBridgeBio Pharma+0.32%-1.39%-5.97%-8.53%+79.96%RGCRegencell Bioscience-6.35%-6.13%-11.46%-3.91%+2,726,999,900.00%TVTXTravere Therapeutics+1.54%+9.56%+47.17%+41.41%+109.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.95Moderate Buy$291.5625.77% UpsideBBIOBridgeBio Pharma 2.92Moderate Buy$87.7127.60% UpsideRGCRegencell Bioscience 1.00SellN/AN/ATVTXTravere Therapeutics 2.69Moderate Buy$47.839.23% UpsideCurrent Analyst Ratings BreakdownLatest TVTX, RGC, ASND, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026TVTXTravere Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$40.00 ➝ $50.005/5/2026TVTXTravere Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $55.005/5/2026TVTXTravere Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $59.005/5/2026TVTXTravere Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$47.00 ➝ $57.005/5/2026TVTXTravere Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $60.004/29/2026BBIOBridgeBio Pharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$95.00 ➝ $102.004/28/2026BBIOBridgeBio Pharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$106.004/27/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.004/24/2026TVTXTravere Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $56.004/16/2026ASNDAscendis Pharma A/S Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$262.00 ➝ $292.004/14/2026TVTXTravere Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $53.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$814.57M17.75N/AN/A($2.97) per share-78.06BBIOBridgeBio Pharma$502.08M26.81N/AN/A($10.77) per share-6.38RGCRegencell BioscienceN/AN/AN/AN/A$0.01 per shareN/ATVTXTravere Therapeutics$490.73M8.24$0.35 per share124.01$1.28 per share34.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M-$4.40N/A22.23N/A-30.85%N/A-19.63%5/7/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.78N/A146.26N/A-144.39%N/A-74.43%5/7/2026 (Estimated)RGCRegencell Bioscience-$3.58MN/AN/AN/AN/AN/AN/AN/AN/ATVTXTravere Therapeutics-$25.55M-$0.23N/A29.99N/A-4.00%-28.38%-3.69%N/ALatest TVTX, RGC, ASND, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21N/AN/AN/A$362.56 millionN/A5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70N/AN/AN/A$178.64 millionN/A5/4/2026Q1 2026TVTXTravere Therapeutics-$0.2420$0.05+$0.2920-$0.40$136.23 million$127.20 million2/24/2026Q4 2025BBIOBridgeBio Pharma-$0.75-$1.00-$0.25-$1.00$150.71 million$154.18 million2/12/2026Q4 2025ASNDAscendis Pharma A/S-$0.06-$0.64-$0.58-$0.65$285.35 million$290.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.040.76BBIOBridgeBio PharmaN/A2.772.68RGCRegencell BioscienceN/AN/AN/ATVTXTravere Therapeutics2.712.742.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%RGCRegencell Bioscience0.13%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma14.23%RGCRegencell BioscienceN/ATVTXTravere Therapeutics4.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBBIOBridgeBio Pharma400195.81 million167.94 millionOptionableRGCRegencell Bioscience10494.49 millionN/AN/ATVTXTravere Therapeutics46092.37 million88.27 millionOptionableTVTX, RGC, ASND, and BBIO HeadlinesRecent News About These CompaniesTravere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says4 hours ago | marketbeat.comQ4 Earnings Forecast for TVTX Issued By HC WainwrightMay 6 at 8:20 AM | marketbeat.comTD Cowen Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $60.00May 5 at 2:26 PM | marketbeat.comTravere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call TranscriptMay 5 at 8:06 AM | seekingalpha.comTravere Therapeutics (NASDAQ:TVTX) Director Roy Baynes Sells 9,750 Shares of StockMay 5 at 5:42 AM | americanbankingnews.comInsider Selling: Travere Therapeutics (NASDAQ:TVTX) Director Sells 9,750 Shares of StockMay 5 at 4:35 AM | insidertrades.comTravere Therapeutics Q1 Earnings Call HighlightsMay 4 at 8:07 PM | marketbeat.comCompared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key MetricsMay 4 at 7:01 PM | zacks.comTravere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue EstimatesMay 4 at 6:10 PM | zacks.comTravere Therapeutics (NASDAQ:TVTX) Director Sells $431,145.00 in StockMay 4 at 4:50 PM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Posts Quarterly Earnings Results, Beats Estimates By $999.24 EPSMay 4 at 4:09 PM | marketbeat.comTravere Therapeutics Reports First Quarter 2026 Financial ResultsMay 4 at 4:01 PM | businesswire.comTravere Therapeutics (TVTX) Is Up 8.9% After Stronger Quarter And Insider Sales Activity – Has The Bull Case Changed?May 4 at 7:54 AM | uk.finance.yahoo.comJennison Associates LLC Trims Stock Holdings in Travere Therapeutics, Inc. $TVTXMay 3 at 6:20 AM | marketbeat.comTravere Therapeutics, Inc. $TVTX Shares Sold by Pictet Asset Management Holding SAMay 2, 2026 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Sets New 52-Week High - Time to Buy?May 1, 2026 | marketbeat.comXOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?April 28, 2026 | zacks.comTravere Therapeutics to Report First Quarter 2026 Financial ResultsApril 27, 2026 | businesswire.comCalamos Advisors LLC Buys Shares of 72,305 Travere Therapeutics, Inc. $TVTXApril 27, 2026 | marketbeat.comImpax Asset Management Group plc Decreases Holdings in Travere Therapeutics, Inc. $TVTXApril 26, 2026 | marketbeat.comTravere Therapeutics (TVTX) Receives a Buy from Piper SandlerApril 26, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTVTX, RGC, ASND, and BBIO Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$234.63 +9.35 (+4.15%) As of 02:36 PM Eastern This is a fair market value price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$68.73 -0.05 (-0.07%) As of 02:36 PM Eastern This is a fair market value price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Regencell Bioscience NASDAQ:RGC$27.84 +0.58 (+2.11%) As of 02:35 PM Eastern This is a fair market value price provided by Massive. Learn more.Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.Travere Therapeutics NASDAQ:TVTX$44.22 -0.58 (-1.28%) As of 02:36 PM Eastern This is a fair market value price provided by Massive. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
